Summit Therapeutics SMMT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's total current liabilities?
- Summit Therapeutics (SMMT) reported total current liabilities of $83.27M in Q1 2026.
- How has Summit Therapeutics's total current liabilities changed year-over-year?
- Summit Therapeutics's total current liabilities increased by 138.7% year-over-year, from $34.88M to $83.27M.
- What is the long-term trend for Summit Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's total current liabilities has grown at a 29.7% compound annual growth rate (CAGR), from $19.89M to $72.99M.
- What does total current liabilities mean?
- The total amount of debt and obligations due within one year.
- How do you interpret total current liabilities?
- A rising trend relative to current assets may indicate liquidity pressure, whereas a stable or declining trend suggests manageable short-term debt.
- How does total current liabilities compare across companies?
- A fundamental liquidity metric used to assess short-term solvency across all sectors.